Ihsan Salloum to Treatment Outcome
This is a "connection" page, showing publications Ihsan Salloum has written about Treatment Outcome.
Connection Strength
0.369
-
Cornelius JR, Chung T, Douaihy AB, Kirisci L, Glance J, Kmiec J, FitzGerald D, Wesesky MA, Salloum I. Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial. Psychiatry Res. 2016 Aug 30; 242:326-330.
Score: 0.091
-
Cornelius JR, Douaihy A, Bukstein OG, Daley DC, Wood SD, Kelly TM, Salloum IM. Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents. Addict Behav. 2011 Aug; 36(8):843-8.
Score: 0.063
-
Salloum IM, Douaihy A, Cornelius JR, Kirisci L, Kelly TM, Hayes J. Divalproex utility in bipolar disorder with co-occurring cocaine dependence: a pilot study. Addict Behav. 2007 Feb; 32(2):410-5.
Score: 0.046
-
Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005 Jan; 62(1):37-45.
Score: 0.041
-
Douaihy AB, Jou RJ, Gorske T, Salloum IM. Triple diagnosis: dual diagnosis and HIV disease, Part 1. AIDS Read. 2003 Jul; 13(7):331-2, 339-41.
Score: 0.037
-
Falk DE, Ryan ML, Fertig JB, Devine EG, Cruz R, Brown ES, Burns H, Salloum IM, Newport DJ, Mendelson J, Galloway G, Kampman K, Brooks C, Green AI, Brunette MF, Rosenthal RN, Dunn KE, Strain EC, Ray L, Shoptaw S, Ait-Daoud Tiouririne N, Gunderson EW, Ransom J, Scott C, Leggio L, Caras S, Mason BJ, Litten RZ. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. Alcohol Clin Exp Res. 2019 01; 43(1):158-169.
Score: 0.027
-
Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A, Smith EV, Kahn R, Chiang N, Vocci F, Ciraulo D, Dackis C, Roache JD, Salloum IM, Somoza E, Urschel HC, Elkashef AM. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009 Sep 01; 104(1-2):133-9.
Score: 0.014
-
Cornelius JR, Clark DB, Bukstein OG, Birmaher B, Salloum IM, Brown SA. Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review. Addict Behav. 2005 Oct; 30(9):1824-33.
Score: 0.011
-
Weiss RD, Ostacher MJ, Otto MW, Calabrese JR, Fossey M, Wisniewski SR, Bowden CL, Nierenberg AA, Pollack MH, Salloum IM, Simon NM, Thase ME, Sachs GS. Does recovery from substance use disorder matter in patients with bipolar disorder? J Clin Psychiatry. 2005 Jun; 66(6):730-5; quiz 808-9.
Score: 0.011
-
Cornelius JR, Clark DB, Bukstein OG, Kelly TM, Salloum IM, Wood DS. Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder: a 3-year follow-up study. Addict Behav. 2005 May; 30(4):807-14.
Score: 0.010
-
Cornelius JR, Bukstein OG, Salloum IM, Kelly TM, Wood DS, Clark DB. Fluoxetine in depressed AUD adolescents: a 1-year follow-up evaluation. J Child Adolesc Psychopharmacol. 2004; 14(1):33-8.
Score: 0.010
-
Weiss RD, Griffin ML, Mazurick C, Berkman B, Gastfriend DR, Frank A, Barber JP, Blaine J, Salloum I, Moras K. The relationship between cocaine craving, psychosocial treatment, and subsequent cocaine use. Am J Psychiatry. 2003 Jul; 160(7):1320-5.
Score: 0.009